Scholarlink

Purpose <p>Surveillance of patient outcomes with real-world data is essential to uncover regional disparities in clinical practice or quality of care. This study explored survival differences among glioblastoma patients in Norway and investigated the role of demographic and treatment factors.</p> Methods <p>We analyzed real-world data from the Norwegian Cancer Registry on 1158 adults with histologically confirmed glioblastoma during 2019–2023. Surgical treatment rates per 100,000 inhabitants per region (South-East, West, Mid, North) were compared using adjusted Poisson models. Full treatment included surgical resection, radiotherapy (≥ 55&#xa0;Gy for ≤ 70 years; ≥30&#xa0;Gy for &gt; 70 years), and temozolomide. Standardized survival was estimated with flexible parametric models, standardized for age, sex, year, and distances to treatment facilities.</p> Results <p>Patients from the North were older and lived further from treatment centers. For patients aged 18–70, treatment and survival did not significantly differ across regions; national median standardized survival was 14.4 months (95%CI:13.6–15.2). For elderly patients (71–89 years), the North demonstrated a higher surgical treatment rate (rate ratio = 1.32; 95%CI = 0.99–1.77), but lesser use of postoperative radiotherapy and temozolomide. Median standardized survival for elderly patients in the North was 4.5 months (95%CI: 3.5–5.7) versus 7.7 (6.9–8.6) months nationally. Early mortality was particularly high for elderly patients in the North, yet those surviving beyond six months matched other regions’ survival probability.</p> Conclusion <p>Lower glioblastoma survival in the North was associated with higher early mortality among elderly patients, likely due to selecting frailer patients for surgery, who less often subsequently received anti-neoplastic treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月11日

查看全文
  • Cassia Bree Trewin-Nybråten,
  • Paul Christopher Lambert,
  • Kirsten Marienhagen,
  • Lasse Andreassen,
  • Tom Børge Johannesen,
  • Pitt Niehusmann,
  • Leif Oltedal,
  • Stephanie Schipmann,
  • Anne Jarstein Skjulsvik,
  • Ole Solheim,
  • Tora Skeidsvoll Solheim,
  • Terje Sundstrøm,
  • Einar Osland Vik-Mo,
  • Petter Brandal,
  • Tor Ingebrigtsen,
  • Erlend Skaga,
  • Rolf Bjerkvig,
  • Hrvoje Miletic,
  • Ine Marie Larsson,
  • Ingeborg Våg,
  • Liv Marit Dørum

摘要

Purpose

Surveillance of patient outcomes with real-world data is essential to uncover regional disparities in clinical practice or quality of care. This study explored survival differences among glioblastoma patients in Norway and investigated the role of demographic and treatment factors.

Methods

We analyzed real-world data from the Norwegian Cancer Registry on 1158 adults with histologically confirmed glioblastoma during 2019–2023. Surgical treatment rates per 100,000 inhabitants per region (South-East, West, Mid, North) were compared using adjusted Poisson models. Full treatment included surgical resection, radiotherapy (≥ 55 Gy for ≤ 70 years; ≥30 Gy for > 70 years), and temozolomide. Standardized survival was estimated with flexible parametric models, standardized for age, sex, year, and distances to treatment facilities.

Results

Patients from the North were older and lived further from treatment centers. For patients aged 18–70, treatment and survival did not significantly differ across regions; national median standardized survival was 14.4 months (95%CI:13.6–15.2). For elderly patients (71–89 years), the North demonstrated a higher surgical treatment rate (rate ratio = 1.32; 95%CI = 0.99–1.77), but lesser use of postoperative radiotherapy and temozolomide. Median standardized survival for elderly patients in the North was 4.5 months (95%CI: 3.5–5.7) versus 7.7 (6.9–8.6) months nationally. Early mortality was particularly high for elderly patients in the North, yet those surviving beyond six months matched other regions’ survival probability.

Conclusion

Lower glioblastoma survival in the North was associated with higher early mortality among elderly patients, likely due to selecting frailer patients for surgery, who less often subsequently received anti-neoplastic treatment.